|
Association between duration of somatostatin analogs (SSAs) use and quality of life in patients with carcinoid syndrome in the United States based on the FACT-G instrument. |
|
|
Consulting or Advisory Role - Novartis; Oxigene |
Research Funding - Dicerna; Genentech/Roche; Ipsen (Inst); Novartis; Novartis (Inst) |
|
|
Research Funding - Novartis (Inst); Pfizer (Inst) |
|
|
Consulting or Advisory Role - FACIT.org; NorthShore University HealthSystem; Novartis |
|
|
|
Stock and Other Ownership Interests - Novartis |
Research Funding - Novartis |
Travel, Accommodations, Expenses - Novartis |
|
|
Research Funding - Novartis (Inst) |
|
|
Stock and Other Ownership Interests - Zafgen |
Research Funding - Novartis (Inst) |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Express Scripts; Valeant Pharmaceuticals International |
Research Funding - Novartis (Inst) |
|
|
|
|
|
Stock and Other Ownership Interests - FACIT.org |
Consulting or Advisory Role - Abbvie; Bayer; GlaxoSmithKline; Pfizer |
Research Funding - Bayer (Inst); Genentech (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bayer; GlaxoSmithKline |